Agenda for Day 2 - Tuesday October 6, 2026Tuesday, 6 October 2026

Join Kernel Solutions for a Solution Summit!

This session explores how automation transforms Medicaid operations, eliminating repetitive, manual tasks and replacing them with timely, actionable financial insight. Across the full financial lifecycle, invoice processing flows directly into Gross‑To‑Net, leveraging dynamic dashboards combined with AI‑driven anomaly detection to deliver real‑time visibility into operational throughput and financial performance, surfacing discrepancies before they escalate into material risk.

Space is limited - make sure to RSVP to secure your seat at this insightful session!

This session provides practical guidance on preparing for, negotiating, and implementing your FSS contract with the VA, including insights on how contracting officers are interpreting the FAR overhaul implementation, the shift to 20-year contract options under mass modifications for 651b, and what's changing in FSS contracting practices

The session will focus on the connection between commercial contracting, Government Pricing, and Medicaid rebate operations:

• Learn how contract terms and transaction economics flow into GP treatment, AMP/Best Price, and ultimately Medicaid rebate liability.

• Operationalizing the rules across multiple teams, systems, data sources, and reporting periods

• Explore examples and issues such as customer and channel classification, effective dating, retroactive true-ups, 340B considerations, exceptions, and the ability to trace a Medicaid or GP outcome all the way back to the underlying commercial agreement and transaction

Government Pricing audits continue to uncover many of the same compliance gaps across manufacturers of every size. The difference today is that organizations no longer need to rely solely on manual reviews, spreadsheets, and resource-intensive assessments. AI and intelligent automation are fundamentally changing how compliance teams identify risk, validate data, and prepare for audits. With more than 20 years of Government Pricing audit and assessment experience, we have seen the common types of gaps and issues across all sizes and type of manufactures, as well as where we can apply innovative technology, such as automating Class of Trade Review instead of time intensive and inefficient manual reviews. Not only is this more efficient and accurate, it provides greater transparency, traceability, and audit-ready documentation.

• Creating an AI-enabled GP Documentation Library to organize and align policies, procedures, reasonable assumptions, methodologies, and supporting evidence into a searchable, continuously maintained knowledge base

• Using AI to evaluate methodology integrity, including validation of domain table mappings, smoothing algorithms, and calculation logic to identify inconsistencies and misalignment to Policy and Procedure documentation before they become audit findings

• Automating Customer Master and Class of Trade analysis Evaluating COT assignment in the Customer Master data, identifying assignment exceptions, and improving the accuracy of 340B eligibility validation

• Building an intelligent Contract Master Reconciling contract data with Government Pricing systems and Accounts Payable while documenting Bona Fide Service Fee determinations and supporting rationale

• Applying AI to data collection, reconciliation, and validation across disparate source systems to improve data quality, reduce manual effort, and accelerate monthly and quarterly reporting cycles

• Leveraging AI for parallel pricing calculations and predictive testing to validate results, identify anomalies, evaluate smoothing methodologies, and strengthen audit readiness before submissions are made

• Assess the 2026 impact of uncapped inflation rebates, identifying legacy SKUs with rebate obligations exceeding 100% of AMP

• Leverage WAC reductions to mitigate inflationary rebates and stabilize gross-to-net (GTN) for at-risk mature portfolios

• Examine MDRP withdrawals and product discontinuations for negative-margin assets, evaluating legal implications for remaining commercial availability

• Consider the GENEROUS model to align Medicaid net prices with international benchmarks, replacing uncapped rebates with negotiated agreements

• Implement cross-functional protocols to manage Medicaid price resets' impact on 340B ceiling prices and commercial rebate guarantees, avoiding revenue erosion

Understand how proposed PBM reforms, FTC transparency initiatives, and evolving market dynamics may reshape manufacturer access, contracting, commercialization, and operational investments

• Understand how PBM reform is disrupting the traditional rebate-driven access model

• Assess why and how PBM incentives may change and our perspective on future influence

• Anticipate the shift from financial controls to clinical and patient access controls

• Prepare for expanding transparency, reporting, and audit requirements

• Discuss considerations manufacturer strategies and operational capabilities needed in the new rebate/fee environment

• Use live polling to uncover how and why peers are adopting AI for pricing, contracting, and compliance

• Benchmark trends on GTN accuracy, 340B disputes, and WAC reset modeling for 2027

• Share success stories and challenges in AI adoption through interactive discussions

• Explore the future of pricing teams, focusing on AI-augmented strategy and essential skills for compliance

As the 340B landscape evolves toward rebate-based administration, covered entities and manufacturers face growing challenges involving upfront drug acquisition costs, duplicate discounts, fragmented claim data, dispute resolution, and retrospective reconciliation.

This session explores 340B claim pre-adjudication as the prospective first step of an effective rebate administration model—identifying and validating 340B appropriateness at the point of sale before downstream rebate processing occurs.

By establishing 340B status at the point of sale and maintaining that designation throughout the claim lifecycle, pre-adjudication can connect eligibility determination with purchasing, rebate administration, payment, reconciliation, and dispute resolution. The objective is to move from predominantly retrospective claim management toward a more prospective, coordinated, and transparent process, enhancing both rebate based model as well as the larger 340B administration business model.

• Expand CAR-T therapies into autoimmune conditions by addressing access challenges in community and specialty settings

• Highlight CGT’s curative value with outcome data, cost comparisons, and hospitalization avoidance metrics

• Tackle hospital margin pressures and DRG-based reimbursement gaps in Medicare Part A, while navigating the 2026 legal landscape of 340B eligibility for specialized biologics

• Operationalize Outcomes-Based Agreements (OBAs) and 'subscription' models aligned with the CMS Cell and Gene Therapy Access Model launching in late 2026

• Optimize manufacturing with automation, scale economies, and logistics tailored to patient-specific products

• Ensure quality and efficiency through robust supply chain and inventory management frameworks